🔴 BreakingDrug approvalRSSYesterday
The FDA has approved Otarmeni, a new gene therapy treatment for genetic hearing loss. This is the first-of-its-kind treatment that uses a special virus to deliver healthy genes into the ear to help restore hearing. The approval was fast-tracked through a special FDA program that prioritizes treatments for serious diseases.
WHY IT MATTERSThis is the first gene therapy approved specifically for inherited hearing loss, offering a potential one-time treatment option for patients with certain genetic forms of deafness who previously had no curative options.
🔴 BreakingDrug approvalRSSApr 3
The FDA approved a new drug called Foundayo (orforglipron) on a special fast-track program called the National Priority Voucher program. This is the fifth drug approved through this program, which helps speed up approval for medicines that address important health needs. The program is designed to get helpful new treatments to patients faster.
WHY IT MATTERSThis approval demonstrates the National Priority Voucher program is working to bring new treatment options to patients with rare diseases more quickly than the standard FDA review process.
PolicyRSSApr 3
The FDA is holding a public meeting to get feedback from patients, doctors, and companies about a pilot program called the Commissioner's National Priority Voucher. This program is designed to speed up the development of drugs for diseases that are considered national health priorities. The FDA wants to hear what people think about how the program is working and how it could be improved.
WHY IT MATTERSIf you have a rare disease, this meeting could influence which diseases the FDA prioritizes for faster drug development in the future—your input or your disease community's input could help shape which conditions get expedited attention.
🔴 BreakingDrug approvalRSSApr 3
The FDA approved a new, stronger version of the weight loss drug Wegovy (semaglutide) at 7.2 mg. This higher dose is intended for adults who need help losing weight and keeping it off long-term. This approval was granted under a special FDA program that prioritizes treatments for rare diseases.
WHY IT MATTERSThis approval under the National Priority Voucher Program suggests semaglutide may address weight management in a rare disease population, though the article does not specify which rare condition qualifies for this higher dose.
🔴 BreakingDrug approvalRSSApr 3
The FDA has approved a new two-drug combination called Tec-Dara to treat multiple myeloma, a blood cancer that has come back or stopped responding to previous treatments. This approval is special because it was fast-tracked through a program that rewards companies for developing medicines for serious diseases. The combination uses two drugs that work together to help patients whose cancer has already been treated at least once before.
WHY IT MATTERSPatients with relapsed or refractory multiple myeloma now have a new treatment option that combines two drugs shown to work together, potentially offering better outcomes for those who have exhausted earlier treatment lines.